Effect of droperidol 2,5 mg added to 100 mg morfine in PCA therapy in combination with ondansetron and dexamethasone against PONV.

Phase 4

Recruiting

• Conditions: postoperative nausea and vomiting; 10017977

• Registration Number: NL-OMON31800
• Lead Sponsor: Amphia Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

18 years and older
postoperative analgesia by means of a PCA pump with morfine

Exclusion Criteria

Pregnancy, breastfeeding, serious depression, bradycardia (<55/min), hypopotassemia, pheochromocytoma, dopamin agonist use, prolonged QT-interval, alcoholism

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint is PONV yes or no. PONV is defines as at least one time<br /><br>vomited of nausea (verbal rating scale 2 or more) within 24 hours<br /><br>postoperative.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are PONV after 48 and 72 hours postoperative, number of<br /><br>times vomited, consumption of morfine, metoclopramide and ondansetron after 24,<br /><br>48 and 72 hours postoperative and number of patients who develop delirium 72<br /><br>hours postoperative. </p><br>